Merck's Keytruda cuts progression risk by 43% in Phase 3 endometrial cancer trial

Merck says its immunotherapy KEYTRUDA reduced the risk of disease progression by 43% in a Phase 3 trial in endometrial cancer.

Detected & updated continuously · Source: Nebula